[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 246
Citations 0
Comment & Response
July 2017

Concerns Regarding Opicapone as Adjunct to Levodopa Therapy–Reply

Author Affiliations
  • 1Reta Lila Weston Institute of Neurological Studies, University College London, London, England
  • 2Research & Development, Bial–Portela & Cª S.A, Porto, Portugal
JAMA Neurol. 2017;74(7):873. doi:10.1001/jamaneurol.2017.0726

In Reply We thank Zhang and Huang for their interest in our article1 and the opportunity to further clarify the points that were made. First, we confirm that the reported study period (March 18, 2011, through June 25, 2013) includes the recruitment period, the 14- to 15-week double-blind phase, and the complete 1-year open-label extension. Recruitment was not selective and it actually took slightly less than a year to enroll all 485 patients, which is within the current expectations for this patient population. Second, 367 patients completed the double-blind phase of the study and agreed to enter the open-label extension. Of these, 286 patients (78%) completed the entire 1-year follow-up period. We do not agree that a 12% rate of dropout during a double-blind study and 22% dropout rate during 1 year of follow-up should be considered unusual or large, and our data are similar to those reported in similar studies conducted among a similar patient population.2,3 Finally, we confirm that all secondary outcomes are accurately described and presented within Table 2 of the article.1

×